{"id":69813,"date":"2023-09-22T16:21:34","date_gmt":"2023-09-22T14:21:34","guid":{"rendered":"https:\/\/cri1149.mlcom-dev.net\/?post_type=publications&#038;p=69813"},"modified":"2025-09-11T16:47:56","modified_gmt":"2025-09-11T14:47:56","slug":"early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life","status":"publish","type":"publication","link":"https:\/\/cri1149.mlcom-dev.net\/en\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/","title":{"rendered":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-69813","publication","type-publication","status-publish","hentry"],"acf":{"numero_de_publication":"Liver Int.","date_de_publication":"20210701","numero_doi":"","equipe":[130],"auteurs-liste":[{"texte_libre":false,"auteur-lien":13023,"auteur-text":""},{"texte_libre":false,"auteur-lien":13214,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Fr\u00e9deric Le Gal"},{"texte_libre":false,"auteur-lien":13127,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"S\u00e9gol\u00e8ne Brichler"},{"texte_libre":false,"auteur-lien":15807,"auteur-text":""},{"texte_libre":false,"auteur-lien":15805,"auteur-text":""},{"texte_libre":false,"auteur-lien":13044,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Nathalie Giuly"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Athenais Gerber"},{"texte_libre":false,"auteur-lien":14870,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Sarah Maylin"},{"texte_libre":false,"auteur-lien":17366,"auteur-text":""},{"texte_libre":false,"auteur-lien":13117,"auteur-text":""},{"texte_libre":false,"auteur-lien":13046,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Emmanuel Gordien"},{"texte_libre":false,"auteur-lien":13112,"auteur-text":""}],"auteurs-manuel":"","liens_externes":null,"liens":[{"lien":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33999515\/"}],"paragraphe":"<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\">Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Bulevirtide (BLV, Hepcludex<sup>\u00ae<\/sup>\u00a0) is an HDV\/HBV entry inhibitor approved in June 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease and positive HDV RNA viral load. This real-life preliminary report described early virological efficacy and safety of BLV in six patients with CHD and compensated liver disease: four patients were treated with the combination of BLV (2 mg\/d in subcutaneous injection) and pegylated interferon (PEG-IFN) and two patients with BLV monotherapy. Four patients treated with combined therapy had a decline of a minimum of 1 log<sub>10<\/sub>\u00a0and 3\/3 of 2 log<sub>10<\/sub>\u00a0of HDV-VL at 12 and 24 weeks, respectively. One patient among four had stopped the treatment at 12 weeks because of thrombocytopenia and an HDV-VL relapse was notified 24 weeks after treatment cessation. Three patients among four (3\/4) had undetectable HDV-VL during the therapy (&lt;100 IU\/ml). One patient (1\/2) treated with BLV monotherapy had a decline of HDV-VL by 1 log<sub>10<\/sub>\u00a0at 8 weeks and 1\/1 by 2 log<sub>10<\/sub>\u00a0at 28 week on-treatment. Two patients among four (2\/4) with combined therapy had normal ALT reached at 4 and 56 weeks. One patient (1\/2) with BLV monotherapy achieves ALT normalization at\u200b 4 weeks on treatment. Hepatitis B surface antigen (HBsAg) levels remain unchanged. Three among six (3\/6) patients had an elevation of total biliary acids without pruritus. These early data generated confirm the interest in this new treatment. Final results will be important to demonstrate long-term clinical benefit (fibrosis reversibility and reduction in hepato-cellular carcinoma [HCC]).<\/p>\r\n<\/div>","paragraphe_en":"<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\">Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Bulevirtide (BLV, Hepcludex<sup>\u00ae<\/sup>\u00a0) is an HDV\/HBV entry inhibitor approved in June 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease and positive HDV RNA viral load. This real-life preliminary report described early virological efficacy and safety of BLV in six patients with CHD and compensated liver disease: four patients were treated with the combination of BLV (2 mg\/d in subcutaneous injection) and pegylated interferon (PEG-IFN) and two patients with BLV monotherapy. Four patients treated with combined therapy had a decline of a minimum of 1 log<sub>10<\/sub>\u00a0and 3\/3 of 2 log<sub>10<\/sub>\u00a0of HDV-VL at 12 and 24 weeks, respectively. One patient among four had stopped the treatment at 12 weeks because of thrombocytopenia and an HDV-VL relapse was notified 24 weeks after treatment cessation. Three patients among four (3\/4) had undetectable HDV-VL during the therapy (&lt;100 IU\/ml). One patient (1\/2) treated with BLV monotherapy had a decline of HDV-VL by 1 log<sub>10<\/sub>\u00a0at 8 weeks and 1\/1 by 2 log<sub>10<\/sub>\u00a0at 28 week on-treatment. Two patients among four (2\/4) with combined therapy had normal ALT reached at 4 and 56 weeks. One patient (1\/2) with BLV monotherapy achieves ALT normalization at\u200b 4 weeks on treatment. Hepatitis B surface antigen (HBsAg) levels remain unchanged. Three among six (3\/6) patients had an elevation of total biliary acids without pruritus. These early data generated confirm the interest in this new treatment. Final results will be important to demonstrate long-term clinical benefit (fibrosis reversibility and reduction in hepato-cellular carcinoma [HCC]).<\/p>\r\n<\/div>","documents":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life - CRI<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life - CRI\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/\" \/>\n<meta property=\"og:site_name\" content=\"CRI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T14:47:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/\",\"name\":\"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life - CRI\",\"isPartOf\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#website\"},\"datePublished\":\"2023-09-22T14:21:34+00:00\",\"dateModified\":\"2025-09-11T14:47:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/cri1149.mlcom-dev.net\/en\/cri-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/cri1149.mlcom-dev.net\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#website\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/\",\"name\":\"CRI - Centre de Recherche sur l'Inflammation\",\"description\":\"Centre de Recherche sur l&#039;Inflammation\",\"publisher\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cri1149.mlcom-dev.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#organization\",\"name\":\"CRI1149\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg\",\"contentUrl\":\"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg\",\"width\":215,\"height\":176,\"caption\":\"CRI1149\"},\"image\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\",\"https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life - CRI","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life - CRI","og_url":"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/","og_site_name":"CRI","article_publisher":"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","article_modified_time":"2025-09-11T14:47:56+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/","url":"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/","name":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life - CRI","isPartOf":{"@id":"https:\/\/cri1149.mlcom-dev.net\/#website"},"datePublished":"2023-09-22T14:21:34+00:00","dateModified":"2025-09-11T14:47:56+00:00","breadcrumb":{"@id":"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cri1149.mlcom-dev.net\/publication\/early-virological-response-in-six-patients-with-hepatitis-d-virus-infection-and-compensated-cirrhosis-treated-with-bulevirtide-in-real-life\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cri1149.mlcom-dev.net\/en\/cri-home\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/cri1149.mlcom-dev.net\/publications\/"},{"@type":"ListItem","position":3,"name":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life"}]},{"@type":"WebSite","@id":"https:\/\/cri1149.mlcom-dev.net\/#website","url":"https:\/\/cri1149.mlcom-dev.net\/","name":"CRI - Centre de Recherche sur l'Inflammation","description":"Centre de Recherche sur l&#039;Inflammation","publisher":{"@id":"https:\/\/cri1149.mlcom-dev.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cri1149.mlcom-dev.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cri1149.mlcom-dev.net\/#organization","name":"CRI1149","url":"https:\/\/cri1149.mlcom-dev.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/","url":"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","contentUrl":"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","width":215,"height":176,"caption":"CRI1149"},"image":{"@id":"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/"]}]}},"post_type":"publication","author_name":"","_links":{"self":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/publication\/69813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/types\/publication"}],"acf:term":[{"embeddable":true,"taxonomy":"equipes","href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/equipes\/130"}],"wp:attachment":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/media?parent=69813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}